MOLLY GROSKREUTZ: Open Payments
NPI 1053173823 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$421 in 9 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $305 · 2025 $421
Food & beverage: $422
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $237 |
| Madrigal Pharmaceuticals | 1 | $59 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $27 |
| Lilly USA, LLC | 1 | $21 |
Products named: ENTYVIO, REZDIFFRA, VOQUEZNA, RINVOQ, VOWST, ZENPEP, OMVOH.
Industry payments across WA — which companies pay providers there.
